Two ARPA‑H awards seeded sizable academic efforts to develop regenerative lymphatic therapies. Rice University secured up to $18.2 million to build the first regenerative treatment for lymphedema, focused on repairing damaged lymphatic vessels, while Georgia Tech received up to $21.8 million to advance novel approaches for lymphatic disease treatment and device development. Both programs emphasize translational engineering and aim to move candidate therapies through preclinical validation toward clinical testing. The grants highlight ARPA‑H’s appetite for high‑risk, high‑impact projects that pair bioengineering with clinical endpoints and create platforms meant to tackle chronic, undertreated conditions. These awards should accelerate device‑biologic integration, manufacturability planning, and early regulatory engagement—components critical to bringing next‑generation regenerative solutions for lymphatic disorders into patient care.